pVHL Polyclonal Antibody
| Code | Size | Price |
|---|
| E-AB-10671-20uL | 20uL | £125.00 |
Quantity:
| E-AB-10671-60uL | 60uL | £172.00 |
Quantity:
| E-AB-10671-120uL | 120uL | £237.00 |
Quantity:
| E-AB-10671-200uL | 200uL | £344.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
Shipping:
Ice packs
Storage:
-20°C
Further Information
Abbreviation:
VHL
Background:
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
Buffer:
PBS with 0.05% sodium azide and 50% glycerol, PH7.4
Concentration:
0.4 mg/mL
Conjugation:
Unconjugated
Dilution:
IHC 1:50-1:200
Immunogen:
Recombinant protein of human VHL
Purification method:
Affinity purification
Target Synonym:
Elongin binding protein;G7 protein;HRCA 1;HRCA1;Protein G7;pVHL;RCA 1;RCA1;VHL 1;VHL;VHL;VHL1;VHLH;Von Hippel Lindau disease tumor suppressor;von Hippel Lindau syndrome;von Hippel Lindau tumor suppressor;Von Hippel Lindau tumor suppressor;E3 ubiquitin protein ligase;Von Hippel-Lindau disease tumor suppressor
UNIProt ID:
P40337